MX344727B - Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas. - Google Patents

Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas.

Info

Publication number
MX344727B
MX344727B MX2013005341A MX2013005341A MX344727B MX 344727 B MX344727 B MX 344727B MX 2013005341 A MX2013005341 A MX 2013005341A MX 2013005341 A MX2013005341 A MX 2013005341A MX 344727 B MX344727 B MX 344727B
Authority
MX
Mexico
Prior art keywords
tnfa antibody
high concentration
liquid formulations
improved high
antigen
Prior art date
Application number
MX2013005341A
Other languages
English (en)
Other versions
MX2013005341A (es
Inventor
Weber Carsten
Fraunhofer Wolfgang
Tschoepe Markus
Neu Michael
Redden Laura
Gastens Martin
Feick Alexander
K Paulson Susan
Zhu Tong
Original Assignee
Abbvie Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46051586&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX344727(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Biotechnology Ltd filed Critical Abbvie Biotechnology Ltd
Publication of MX2013005341A publication Critical patent/MX2013005341A/es
Publication of MX344727B publication Critical patent/MX344727B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una formulación farmacéutica líquida acuosa que comprende un anticuerpo anti-TNF-alfa, o una porción de unión al antígeno del mismo, el cual reduce el dolor asociado con la inyección en un sujeto, en al menos aproximadamente 50% cuando se compara con la inyección de una formulación de cualquier otra manera idéntica, que comprende al menos una sal y/o al menos un amortiguador. La invención también proporciona una formulación farmacéutica líquida acuosa que comprende un anticuerpo anti-TNF-alfa, o una porción de unión al antígeno del mismo, que tiene una mayor biodisponibilidad luego de la administración subcutánea en un sujeto. La formulación puede comprender una proteína terapéutica, tal como un anticuerpo anti-TNF-alfa, o una porción de unión al antígeno del mismo, o un biosimilar del mismo.
MX2013005341A 2010-11-11 2011-11-11 Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas. MX344727B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41272810P 2010-11-11 2010-11-11
US41396010P 2010-11-15 2010-11-15
PCT/US2011/060388 WO2012065072A2 (en) 2010-11-11 2011-11-11 IMPROVED HIGH CONCENTRATION ANTI-TNFα ANTIBODY LIQUID FORMULATIONS

Publications (2)

Publication Number Publication Date
MX2013005341A MX2013005341A (es) 2013-07-05
MX344727B true MX344727B (es) 2017-01-05

Family

ID=46051586

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013005341A MX344727B (es) 2010-11-11 2011-11-11 Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas.

Country Status (28)

Country Link
US (5) US8821865B2 (es)
EP (1) EP2637690B1 (es)
JP (3) JP5919606B2 (es)
KR (1) KR101841527B1 (es)
CN (2) CN103458926B (es)
AU (2) AU2011325974B2 (es)
BR (1) BR112013011699B1 (es)
CA (1) CA2815689C (es)
CY (1) CY1118373T1 (es)
DK (1) DK2637690T3 (es)
ES (1) ES2601202T3 (es)
HR (1) HRP20161753T1 (es)
HU (1) HUE029457T2 (es)
IL (1) IL226217A (es)
LT (1) LT2637690T (es)
ME (1) ME02506B (es)
MX (1) MX344727B (es)
NZ (1) NZ609469A (es)
PL (1) PL2637690T3 (es)
PT (1) PT2637690T (es)
RS (1) RS55385B1 (es)
RU (2) RU2639386C2 (es)
SG (2) SG2014015069A (es)
SI (1) SI2637690T1 (es)
SM (1) SMT201600443B (es)
TW (2) TWI606840B (es)
WO (1) WO2012065072A2 (es)
ZA (1) ZA201406542B (es)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090280065A1 (en) * 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
WO2006125229A2 (en) 2005-05-16 2006-11-23 Abbott Biotechnology Ltd. Use of tnf inhibitor for treatment of erosive polyarthritis
ES2776657T3 (es) * 2005-06-14 2020-07-31 Amgen Inc Formulaciones de proteínas autotamponantes
EP1933852B1 (en) 2005-09-27 2018-12-19 TissueTech, Inc. Amniotic membrane preparations and purified compositions and methods of use
US9605064B2 (en) * 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
EP2235059B1 (en) 2007-12-26 2015-02-18 Xencor, Inc. Fc variants with altered binding to fcrn
EP3572796B8 (en) 2008-10-27 2023-01-18 Genalyte, Inc. Biosensors based on optical probing and sensing
LT2637690T (lt) 2010-11-11 2016-10-25 Abbvie Biotechnology Ltd Didelės koncentracijos anti-tnfalfa antikūno skystos kompozicijos
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2012149486A1 (en) 2011-04-28 2012-11-01 Tissuetech, Inc. Methods of modulating bone remodeling
CA2837878A1 (en) 2011-06-10 2012-12-13 Tissuetech, Inc. Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof
GB201112429D0 (en) 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US20150150982A1 (en) * 2012-06-12 2015-06-04 Boehringer Ingelheim International Gmbh Pharmaceutical formulation for a therapeutic antibody
CN104619352B (zh) 2012-07-11 2022-02-18 组织技术公司 含有hc-ha/ptx3复合物的组合物及其使用方法
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
PT2892550T (pt) 2012-09-07 2020-03-27 Coherus Biosciences Inc Formulações aquosas estáveis de adalimumab
WO2014064637A1 (en) * 2012-10-26 2014-05-01 Lupin Limited Stable pharmaceutical composition of tnfr:fc fusion protein
WO2014099636A1 (en) * 2012-12-18 2014-06-26 Merck Sharp & Dohme Corp. Liquid formulations for an anti-tnf alpha antibody
KR20150110659A (ko) 2013-01-24 2015-10-02 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Tnf-알파 항원-결합 단백질
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
CA2899449A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. Low acidic species compositions and methods for producing the same using displacement chromatography
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
AU2013384204B2 (en) 2013-03-14 2017-03-16 Abbvie Inc. Low acidic species compositions and methods for producing and using the same
RU2662558C2 (ru) 2013-07-19 2018-07-26 Хексаль Аг Способы и композиции, которые обеспечивают модуляцию иммунных ответов, связанных с введением биофармацевтического лекарственного средства
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
JP6526025B2 (ja) 2013-10-16 2019-06-05 オンコバイオロジクス，インコーポレイティド 抗体安定性を増強する緩衝液製剤
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EP3125928A4 (en) * 2014-04-02 2017-11-29 Intas Pharmaceuticals Ltd. Liquid pharmaceutical composition of adalimumab
ES2572919T3 (es) 2014-05-23 2016-06-03 Ares Trading S.A. Composición farmacéutica líquida
ES2607489T3 (es) 2014-05-23 2017-03-31 Ares Trading S.A. Composición farmacéutica líquida
EP2946765B1 (en) 2014-05-23 2016-08-31 Ares Trading S.A. Liquid pharmaceutical composition
TW201603818A (zh) 2014-06-03 2016-02-01 組織科技股份有限公司 組成物及方法
JP7037885B2 (ja) * 2014-06-30 2022-03-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ｐＨ依存性抗原結合を示す抗ＴＮＦａ抗体
KR102500075B1 (ko) * 2014-10-08 2023-02-16 아지노모토 가부시키가이샤 평가 방법, 평가 장치, 평가 프로그램, 평가 시스템, 및 단말 장치
TW201628649A (zh) 2014-10-09 2016-08-16 再生元醫藥公司 減少醫藥調配物中微可見顆粒之方法
WO2016118707A1 (en) 2015-01-21 2016-07-28 Oncobiologics, Inc. Modulation of charge variants in a monoclonal antibody composition
US20160243288A1 (en) 2015-02-23 2016-08-25 Tissuetech, Inc. Apparatuses and methods for treating ophthalmic diseases and disorders
EP3078675A1 (en) 2015-04-10 2016-10-12 Ares Trading S.A. Induction dosing regimen for the treatment of tnf alpha mediated disorders
CA2984443A1 (en) 2015-05-20 2016-11-24 Tissuetech, Inc. Compositions and methods for preventing the proliferation and epithelial-mesenchymal transition of epithelial cells
EP3328883A1 (en) 2015-07-31 2018-06-06 GlaxoSmithKline Intellectual Property Development Limited Antibody variants
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
TW201733600A (zh) 2016-01-29 2017-10-01 帝聖工業公司 胎兒扶持組織物及使用方法
CA3013336A1 (en) * 2016-02-03 2017-08-10 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
KR102369014B1 (ko) 2016-08-16 2022-03-02 리제너론 파아마슈티컬스, 인크. 혼합물로부터 개별 항체들을 정량하는 방법
AU2017345454B2 (en) 2016-10-19 2024-10-31 Invenra Inc. Antibody constructs
WO2018075818A1 (en) 2016-10-21 2018-04-26 Amgen Inc. Pharmaceutical formulations and methods of making the same
ES2924060T3 (es) 2016-10-25 2022-10-04 Regeneron Pharma Procedimientos y sistema para análisis de datos de cromatografía
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
BR112019013107A2 (pt) 2016-12-22 2019-12-17 Università Degli Studi Magna Graecia Catanzaro anticorpos, molécula de ligação, receptor de antígeno quimérico, vetor de expressão, composição farmacêutica, linfócito, ácido nucleico, célula de hibridoma, método para a produção do anticorpo monoclonal e usos
CN108239150A (zh) 2016-12-24 2018-07-03 信达生物制药(苏州)有限公司 抗pcsk9抗体及其用途
JOP20190162A1 (ar) 2016-12-30 2019-06-27 Biocad Joint Stock Co تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني
RU2665966C2 (ru) * 2016-12-30 2018-09-05 Закрытое Акционерное Общество "Биокад" Водная фармацевтическая композиция рекомбинантного моноклонального антитела к ФНОα
NZ757965A (en) * 2017-03-16 2022-07-01 Lg Chemical Ltd Liquid formulation of anti-tnf alpha antibody
KR20190024572A (ko) * 2017-08-30 2019-03-08 (주)셀트리온 TNFα 관련 질환을 치료하기 위한 피하 투여 요법
WO2019060062A1 (en) 2017-09-19 2019-03-28 Regeneron Pharmaceuticals Inc. METHODS OF REDUCING PARTICLE FORMATION AND COMPOSITIONS FORMED THEREFROM
WO2019057631A1 (en) * 2017-09-20 2019-03-28 Alvotech Hf PHARMACEUTICAL FORMULATIONS FOR ADALIMUMAB
US20210031012A1 (en) 2018-01-26 2021-02-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
US20210231651A1 (en) * 2018-04-30 2021-07-29 Genalyte, Inc. Methods and compositions for point of care measurement of the bioavailability of therapeutic biologics
IL322895A (en) 2018-06-05 2025-10-01 King S College London Btnl3/8-targeted constructs for delivery of cargo to the digestive system
EP3810085A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US20210363233A1 (en) 2018-06-20 2021-11-25 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
EP3810095A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
US12171764B2 (en) 2018-06-20 2024-12-24 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
TWI853823B (zh) 2018-07-02 2024-09-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
JP7407723B2 (ja) * 2018-09-14 2024-01-04 田辺三菱製薬株式会社 ヒト抗ｉｌ－３３モノクローナル抗体含有医薬用組成物
US11634485B2 (en) * 2019-02-18 2023-04-25 Eli Lilly And Company Therapeutic antibody formulation
US20230203147A1 (en) * 2019-03-18 2023-06-29 Alvotech Hf Aqueous formulations of tnf-alpha antibodies in high concentrations
KR102676428B1 (ko) * 2019-07-08 2024-06-19 가부시키가이샤 모레스코 마이크로에멀션을 조제하기 위한 조성물, 마이크로에멀션, 이들의 제조 방법, 및 마이크로에멀션의 이용
CN111420049A (zh) * 2019-08-22 2020-07-17 Biocad股份公司 抗-pd1抗体prolgolimab的水性药物组合物及其应用
JP6667043B1 (ja) * 2019-10-25 2020-03-18 株式会社Moresco マイクロエマルション、及びマイクロエマルションの利用

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5237054A (en) 1987-02-20 1993-08-17 Akzo Pharma Stabilized aqueous composition containing antibodies
CA2064915C (en) 1989-08-07 2001-05-29 Deborah A. Rathjen Tumour necrosis factor binding ligands
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
JPH0565233A (ja) 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
US20060246073A1 (en) 1991-03-18 2006-11-02 Knight David M Anti-TNF antibodies and peptides of human tumor necrosis factor
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US6165467A (en) 1991-07-20 2000-12-26 Yoshihide Hagiwara Stabilized human monoclonal antibody preparation
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
US5358708A (en) 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
ZA955642B (en) 1994-07-07 1997-05-06 Ortho Pharma Corp Lyophilized imaging agent formulation
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
ATE239041T1 (de) 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
GB9705810D0 (en) 1997-03-20 1997-05-07 Common Services Agency Intravenous immune globulin
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ES2182202T5 (es) 1997-10-23 2007-12-01 Mitsubishi Pharma Corporation Preparacion de inmunoglobulinas para inyeccion intravenosa apta para ser almacenada a temperatura ambiente.
EP1174148A4 (en) 1999-04-28 2005-05-04 Yamanouchi Pharma Co Ltd PARENTAL MEDICAL COMPOSITIONS CONTAINING FRAGMENTS OF HUMANIZED MONOCLONAL ANTIBODIES AND METHOD FOR STABILIZING THE SAME
AU2228901A (en) 1999-12-28 2001-07-09 Chugai Seiyaku Kabushiki Kaisha Stable antibody compositions and injection preparations
DE10022092A1 (de) 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
JP4555436B2 (ja) * 2000-06-29 2010-09-29 富士通株式会社 薄膜樹脂基板への樹脂モールド方法及び高周波モジュール
WO2002011753A1 (en) * 2000-08-04 2002-02-14 Chugai Seiyaku Kabushiki Kaisha Protein injection preparations
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
WO2002013860A1 (en) 2000-08-11 2002-02-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing preparations
SE0003045D0 (sv) 2000-08-29 2000-08-29 Probi Ab New method
CA2423227C (en) 2000-10-12 2011-11-29 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US20030012786A1 (en) 2001-05-25 2003-01-16 Teoh Leah S. Use of anti-TNF antibodies as drugs in treating septic disorders of anemic patients
WO2002098445A1 (fr) 2001-05-30 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preparation de proteines
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
IL159048A0 (en) 2001-06-21 2004-05-12 Genentech Inc Sustained release formulation
DE60235013D1 (de) * 2001-07-25 2010-02-25 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
JP4342941B2 (ja) 2001-08-29 2009-10-14 中外製薬株式会社 抗体含有安定化製剤
US6818613B2 (en) 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
NZ532896A (en) 2001-11-08 2007-08-31 Pdl Biopharma Inc Stable liquid pharmaceutical formulation of IGG antibodies including daclizumab and fontolizumab
GB0202633D0 (en) 2002-02-05 2002-03-20 Delta Biotechnology Ltd Stabilization of protein preparations
KR101080021B1 (ko) 2002-02-14 2011-11-04 추가이 세이야쿠 가부시키가이샤 항체함유 용액제제
US20030161828A1 (en) 2002-02-19 2003-08-28 Abbott Gmbh & Co. Kg Use of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure
US20030180287A1 (en) 2002-02-27 2003-09-25 Immunex Corporation Polypeptide formulation
US20040009172A1 (en) 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20060182740A1 (en) 2002-06-21 2006-08-17 Biogen Idec, Inc. Buffered formulations for concentrating antibodies and methods of use thereof
CN101745112A (zh) 2002-07-19 2010-06-23 艾博特生物技术有限公司 TNFα相关疾病的治疗
US20090280065A1 (en) 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
WO2004055164A2 (en) 2002-12-13 2004-07-01 Abgenix, Inc. System and method for stabilizing antibodies with histidine
JP4728948B2 (ja) 2003-02-10 2011-07-20 エラン ファーマシューティカルズ，インコーポレイテッド 免疫グロブリン製剤およびその調製の方法
EP1603596B1 (en) 2003-02-28 2008-05-07 Ares Trading S.A. Liquid formulations of tumor necrosis factor-binding protein tbp-1
AU2004216298B2 (en) 2003-02-28 2009-04-23 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations
SI2335725T1 (sl) 2003-04-04 2017-01-31 Genentech, Inc. Visokokoncentrirane formulacije protiteles in proteinov
FR2853551B1 (fr) 2003-04-09 2006-08-04 Lab Francais Du Fractionnement Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee
US7344716B2 (en) * 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
DK1698640T4 (da) 2003-10-01 2019-09-02 Kyowa Hakko Kirin Co Ltd Fremgangsmåde til stabilisering af antistof og antistofpræparat som stabiliseret opløsning.
EP1712240B1 (en) 2003-12-25 2015-09-09 Kyowa Hakko Kirin Co., Ltd. Stable water-based medicinal preparation containing antibody
EP1722819B1 (en) 2004-03-12 2007-12-26 Intercell AG Method for solubilising peptide mixtures
TWI556829B (zh) 2004-04-09 2016-11-11 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
JP2008500995A (ja) 2004-06-01 2008-01-17 アレス トレーディング ソシエテ アノニム タンパク質安定化法
WO2006041970A2 (en) 2004-10-08 2006-04-20 Abbott Biotechnology Ltd. Treatment of respiratory syncytial virus (rsv) infection
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CN101111264A (zh) 2005-01-28 2008-01-23 惠氏公司 稳定化的液体多肽制剂
TWI398272B (zh) 2005-03-08 2013-06-11 Intervet Int Bv 化學定義的安定劑
WO2006125229A2 (en) 2005-05-16 2006-11-23 Abbott Biotechnology Ltd. Use of tnf inhibitor for treatment of erosive polyarthritis
WO2006125207A2 (en) 2005-05-19 2006-11-23 Amgen Inc. Compositions and methods for increasing the stability of antibodies
ES2776657T3 (es) 2005-06-14 2020-07-31 Amgen Inc Formulaciones de proteínas autotamponantes
DK1899462T3 (da) 2005-07-02 2011-06-06 Arecor Ltd Stabile vandige systemer omfattende proteiner
WO2007016562A2 (en) 2005-07-29 2007-02-08 Amgen Inc. Formulations that inhibit protein aggregation
KR101566393B1 (ko) 2005-08-03 2015-11-05 이뮤노젠 아이엔씨 면역접합체 제형
WO2007037795A2 (en) 2005-08-05 2007-04-05 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
TWI424161B (zh) 2005-11-01 2014-01-21 Abbvie Biotechnology Ltd 利用生物標記診斷關節黏連脊椎炎之方法及組合物
JP5405122B2 (ja) 2005-12-21 2014-02-05 ワイス・エルエルシー 低粘度のタンパク質製剤およびその用途
JP2009525986A (ja) 2006-02-03 2009-07-16 メディミューン，エルエルシー タンパク質製剤
ES2391657T3 (es) 2006-02-07 2012-11-28 Shire Human Genetic Therapies, Inc. Composiciones estabilizadas de proteínas que tienen un resto tiol libre
TWI392684B (zh) 2006-04-05 2013-04-11 亞培生物科技公司 抗體之純化
US20080118496A1 (en) 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
WO2007120656A2 (en) 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of rheumatoid arthritis
US20090317399A1 (en) 2006-04-10 2009-12-24 Pollack Paul F Uses and compositions for treatment of CROHN'S disease
WO2007120626A2 (en) 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of ankylosing spondylitis
EP2666472A3 (en) 2006-04-10 2014-04-02 Abbott Biotechnology Ltd Uses and compositions for treatment of psoriatic arthritis
US20080131374A1 (en) 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
JP2009534390A (ja) 2006-04-21 2009-09-24 アムジェン インコーポレイテッド 生物医薬品製剤のための緩衝剤
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US20100021451A1 (en) 2006-06-08 2010-01-28 Wong Robert L Uses and compositions for treatment of ankylosing spondylitis
US20080311043A1 (en) 2006-06-08 2008-12-18 Hoffman Rebecca S Uses and compositions for treatment of psoriatic arthritis
US7571225B2 (en) 2006-06-29 2009-08-04 Stratavia Corporation Standard operating procedure automation in database administration
KR101396797B1 (ko) 2006-06-30 2014-05-26 애브비 바이오테크놀로지 리미티드 자동 주사 장치
CA2842964A1 (en) 2006-09-13 2008-03-20 Abbvie Inc. Cell culture improvements
US20100129379A1 (en) 2006-09-25 2010-05-27 John Carpenter Stabilized antibody formulations and uses thereof
JP5631591B2 (ja) 2006-10-06 2014-11-26 アムジエン・インコーポレーテツド 安定な抗体製剤
MX2009003982A (es) 2006-10-20 2009-04-27 Amgen Inc Formulaciones de polipeptido estables.
CN104072612A (zh) 2006-10-27 2014-10-01 艾伯维生物技术有限公司 结晶型抗-hTNFα抗体
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
CN101605532A (zh) 2007-02-16 2009-12-16 惠氏公司 含有山梨糖醇的蛋白质调配物
WO2008134310A1 (en) 2007-04-26 2008-11-06 Bayer Healthcare Llc Stabilization of liquid solutions of recombinant protein for frozen storage
CA2685372A1 (en) 2007-05-02 2008-11-13 F. Hoffmann-La Roche Ag Method for stabilizing a protein
US8092998B2 (en) 2007-05-31 2012-01-10 Abbott Laboratories Biomarkers predictive of the responsiveness to TNFα inhibitors in autoimmune disorders
WO2008150490A2 (en) 2007-06-01 2008-12-11 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriasis and crohn's disease
JP2010530846A (ja) 2007-06-01 2010-09-16 アコロジックス インコーポレイティッド 高温で安定なペプチド製剤
US8999337B2 (en) 2007-06-11 2015-04-07 Abbvie Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
WO2009006301A2 (en) 2007-06-29 2009-01-08 Battelle Memorial Institute Protein stabilization
US20090110679A1 (en) 2007-07-13 2009-04-30 Luk-Chiu Li Methods and compositions for pulmonary administration of a TNFa inhibitor
CN101980722A (zh) 2007-08-08 2011-02-23 雅培制药有限公司 结晶抗体的组合物和方法
WO2009032128A1 (en) 2007-08-28 2009-03-12 Abbott Biotechnology Ltd. Compositions and methods comprising binding proteins for adalimumab
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
KR20210049186A (ko) * 2007-11-30 2021-05-04 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
MX2010007393A (es) 2008-01-03 2010-11-09 Abbott Biotech Ltd Anticipacion de eficacia a largo plazo de un compuesto en el tratamiento de psoriasis.
RU2537139C2 (ru) 2008-01-15 2014-12-27 Эбботт Гмбх Унд Ко.Кг Порошковые белковые композиции и способы их получения
US8187836B2 (en) 2008-01-15 2012-05-29 Abbott Laboratories Mammalian expression vectors and uses thereof
CN102282173A (zh) 2008-03-24 2011-12-14 艾博特生物技术有限公司 用于治疗骨丢失的方法和组合物
CA2760237C (en) 2009-04-29 2017-11-14 Abbott Biotechnology Ltd. Automatic injection device and plunger for same
SG10201401995UA (en) * 2009-05-04 2014-08-28 Abbvie Biotechnology Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
WO2011097301A2 (en) 2010-02-02 2011-08-11 Abbott Biotechnology Ltd. METHODS AND COMPOSITIONS FOR PREDICTING RESPONSIVENESS TO TREATMENT WITH TNF-α INHIBITOR
MX2012014080A (es) 2010-06-03 2013-05-01 Abbvie Biotechnology Ltd Usos y composiciones para el tratamiento de hidradenitis superativa (hs).
LT2637690T (lt) 2010-11-11 2016-10-25 Abbvie Biotechnology Ltd Didelės koncentracijos anti-tnfalfa antikūno skystos kompozicijos

Also Published As

Publication number Publication date
US20120263731A1 (en) 2012-10-18
RU2015154965A (ru) 2019-01-16
TWI606840B (zh) 2017-12-01
MX2013005341A (es) 2013-07-05
TW201641119A (zh) 2016-12-01
PT2637690T (pt) 2016-12-27
TW201244736A (en) 2012-11-16
SG2014015069A (en) 2014-07-30
TWI603739B (zh) 2017-11-01
JP6062582B2 (ja) 2017-01-18
AU2011325974A1 (en) 2013-05-09
JP2016172740A (ja) 2016-09-29
SI2637690T1 (sl) 2016-11-30
EP2637690B1 (en) 2016-09-21
ME02506B (me) 2017-02-20
SG190069A1 (en) 2013-06-28
AU2011325974B2 (en) 2016-10-27
KR20130135266A (ko) 2013-12-10
CN103458926B (zh) 2016-10-26
LT2637690T (lt) 2016-10-25
DK2637690T3 (da) 2017-01-02
JP2016128466A (ja) 2016-07-14
CY1118373T1 (el) 2017-06-28
NZ609469A (en) 2015-02-27
RU2013126655A (ru) 2014-12-20
EP2637690A2 (en) 2013-09-18
BR112013011699A2 (pt) 2015-09-29
IL226217A0 (en) 2013-07-31
US20140377275A1 (en) 2014-12-25
PL2637690T3 (pl) 2017-03-31
WO2012065072A2 (en) 2012-05-18
AU2016202136A1 (en) 2016-04-28
SMT201600443B (it) 2017-01-10
US20160017030A1 (en) 2016-01-21
CA2815689A1 (en) 2012-05-18
CN105854016A (zh) 2016-08-17
US20190211093A1 (en) 2019-07-11
KR101841527B1 (ko) 2018-03-23
JP2013543868A (ja) 2013-12-09
HUE029457T2 (en) 2017-02-28
RS55385B1 (sr) 2017-03-31
ZA201406542B (en) 2015-09-30
JP5919606B2 (ja) 2016-05-18
WO2012065072A3 (en) 2012-07-26
US8821865B2 (en) 2014-09-02
RU2639386C2 (ru) 2017-12-21
ES2601202T3 (es) 2017-02-14
EP2637690A4 (en) 2014-04-30
IL226217A (en) 2017-08-31
CN103458926A (zh) 2013-12-18
US20220010005A1 (en) 2022-01-13
CA2815689C (en) 2016-11-22
HRP20161753T1 (hr) 2017-02-10
BR112013011699B1 (pt) 2019-04-24
HK1189162A1 (zh) 2014-05-30

Similar Documents

Publication Publication Date Title
MX344727B (es) Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas.
MX2011011772A (es) Formulaicones estables de anticuerpos humanos anti-tnf-alfa con alta concentracion de proteina.
WO2015024667A8 (en) Method for increasing expression of rna-encoded proteins
MY188825A (en) High-concentration monoclonal antibody formulations
SG10201806539XA (en) Liquid protein formulations containing ionic liquids
WO2014165607A3 (en) Aromatic-cationic peptide formulations, compositions and methods of use
HK1208629A1 (en) Hgh-xten fusion protein and its use in the treatment of growth hormone deficiency
IL224048B (en) Antiganic composition comprising whole killed or attenuated pathogenic eschrichia coli ( e.coli) cells for intradermal or subcutaneous administration for treating a human patient for crohn's disease
EA201492292A1 (ru) Препарат антител
NZ711567A (en) Antibody formulations
WO2011109365A3 (en) Concentrated protein formulations and uses thereof
UA117103C2 (uk) Сполука, яка має активність агоніста глюкагону
EA201501054A1 (ru) Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы
EP4534107A3 (en) Protein complex by use of a specific site of an immunoglobulin fragment for linkage
AU2016204185A1 (en) Methods of administering beta7 integrin antagonists
HRP20171931T1 (hr) Farmaceutska formulacija koja obuhvaća biofarmaceutski lijek
RU2016105462A (ru) Способы и композиции, которые обеспечивают модуляцию иммунных ответов, связанных с введением биофармацевтического лекарственного средства
WO2014204988A3 (en) 5t4-targeted immunofusion molecule and methods
HRP20191137T1 (hr) Formulacije otopina konstruiranih anti-il-23p19 antitijela
NZ702342A (en) Pharmaceutical formulation
SE0301663D0 (sv) Analysmetod för infusionsläkemedel
BR112018008769A2 (pt) formulações farmacêuticas, formulações líquidas aquosa reconstituída e liofilizada, seringa, método de fabricação de uma formulação farmacêutica, método para tratamento de uma doença e uso de uma formulação reconstruída
MX383557B (es) Formulaciones inyectables de paracetamol.
HK1226323A1 (en) Liquid protein formulations containing ionic liquids
HK1226310A1 (en) Liquid protein formulations containing water soluble organic dyes

Legal Events

Date Code Title Description
FG Grant or registration
GD Licence granted